Unpacking Negative Symptoms, Medication Adverse Effects, and Emerging Schizophrenia Treatments

Psych Congress Steering Committee Member Jonathan Meyer, MD, voluntary clinical professor of psychiatry at the University of California San Diego, discusses the challenges in managing schizophrenia, particularly focusing on the persistence of negative cognitive symptoms despite current antipsychotic treatments. He unpacks how the adverse effects of current antipsychotic medications contribute to high non-adherence rates and the strategies that can be implemented to mitigate those issues. Dr Meyer also sheds light on muscarinic receptor activators and their potential benefits compared to traditional antipsychotic treatments, offering insights into the revolutionary treatment approaches for schizophrenia.

Visit the Schizophrenia Learning Library for more schizophrenia rapid refreshers, clinical pearls, and perspectives from Dr Meyer and other experts in the field.

Jonathan Meyer, MD, is a voluntary clinical professor of psychiatry at University of California, San Diego, and a Distinguished Life Fellow of the American Psychiatric Association. Dr Meyer also has teaching duties at UC San Diego and the Balboa Naval Medical Center in San Diego, is a consultant to the first episode psychosis program at Balboa NMC, and is a Senior Academic Advisor to the California Department of State Hospitals. Dr Meyer has lectured and published extensively on psychopharmacology, and is the sole author of the chapter on the Pharmacotherapy of Psychosis and Mania for the last 3 editions of Goodman & Gilman's The Pharmacological Basis of Therapeutics. Along with Dr Stephen Stahl he is co-author of The Clozapine Handbook published in 2019, The Clinical Use of Antipsychotic Plasma Levels published in 2021, and The Lithium Handbook published in 2023.

Transcript coming soon.